Drugs / PEG IL-2
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00001036 | — | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00002017 | — | HIV infectious disease | Rockefeller University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEG-IL-2 | “polyethylene glycolated-interleukin-2 (PEG-IL-2)” NCT00002017 ↗1“polyethylene glycolated interleukin-2 (PEG IL-2)” NCT00001036 ↗ |
| Known as | polyethylene glycolated-interleukin-2 | “polyethylene glycolated-interleukin-2 (PEG-IL-2)” NCT00002017 ↗1“polyethylene glycolated interleukin-2 (PEG IL-2)” NCT00001036 ↗ |
| Route | Subcutaneous | “either the intradermal (ID) or subcutaneous (SC) route” NCT00002017 ↗ |